First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
Vieworks to Highlight Its X-ray Flat Panel Detectors Lineup at ECR 2022
Amazon Celebrates Prime Members With New, Exclusive Offers and Experiences
Node4 acquires risual to strengthen Microsoft Cloud capabilities and UK Public Sector footprint aligning with existing Microsoft capabilities to drive
SoSafe hires former Smartly.io exec and SaaS leader Felix Fichtl as CFO to continue the firm’s recent growth
KEENON Robotics Showcases Foodservice Robots at Meat Food Expo - Yakiniku Business Fair 2022
Farrer Park Hospital Underscores Commitment to Sustainability with Ongoing Green Initiatives
ECR Minerals plc UK Regulatory Announcement: Investor Presentation and Strategic Update
Arab Fund for Economic and Social Development Names Northern Trust Its Asset Servicing Provider
Hoffmann Green Opens Its First International Subsidiary With a Partner in Switzerland
-
Westchester Capital Management UK Regulatory Announcement: Form 8.3 - HomeServe plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Westchester Capital Management, LLC/ Westchester Capital Partners, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree HomeServe plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure July 5, 2022 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 2 9/13p ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 5,808,355 1.73 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 5,808,355 1.73 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 2 9/13p ordinary CFD Increasing long 995 1166.0 GBp (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” none (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” none (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? no Date of disclosure: July 5, 2022 Contact name: Michael Bauco Telephone number: 914 741 5600 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. Contacts Westchester Capital Management
-
Wasatch Advisors UK Regulatory Announcement: Form 8.3 - Ideagen PLC
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Wasatch Advisors, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Ideagen PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 05/07/2022 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” NO 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 1p ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 4,653,511 1.58% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 4,653,511 1.58% All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit 1p ordinary Purchase 36,152 3.50 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 05/07/2022 Contact name: Rebekah Gold Telephone number*: 801 533 0777 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. Contacts Wasatch Advisors Inc.
-
Toyoda Gosei to Invest in Interior and Exterior Parts Manufacturing Company in Central China
KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. (TOKYO:7282), through its regional headquarters in China, Toyoda Gosei (China) Investment Co., Ltd. (TG China), is investing in Wuhan Binyu Auto. Part Co., Ltd. This move will strengthen Toyoda Gosei’s supply system for interior and exterior automotive parts in central China. Wuhan Binyu is a production company in the Yibin Group (Ningbo Yibin Electronic Technology Corp.) that supplies interior and exterior automotive parts in China’s major automobile manufacturing regions (north China, south China, central China). It provides console boxes and cockpit components to Dongfeng Honda Automobile Co., Ltd. and Dongfeng Motor Co., Ltd. (Dongfeng Nissan) in central China. With this investment, the Toyoda Gosei Group aims to grow its sales in China by merging its engineering and production expertise as a global supplier of plastic parts with the business partnership that Ningbo Yibin has built over many years with automakers in China. Outline of Wuhan Binyu (investee company) Company name Current: Wuhan Binyu Auto. Part Co., Ltd. New: Yibin Toyoda Gosei (Wuhan) Auto Parts Co., Ltd. Location Wuhan, Hubei, China Established June 2013 Capital CNY 20.0 million Shareholders Current: Ningbo Yibin 100% New: Ningbo Yibin 66% Toyoda Gosei (China) Invest. Co., Ltd. 34%* Products Interior and exterior products (consoles, registers, more) Land area Building area Approx. 27,000 m2 Approx. 32,000 m2 No. employees 174 (as of May 31, 2022) * TG China purchased 34% of shares from Ningbo Yibin for approx. JPY 350 million. Calculated at 1 Chinese yuan = 17.5 Japanese yen Outline of Ningbo Yibin Name Ningbo Yibin Electronic Technology Corp. Location Ningbo, Zhejiang, China Established August 2006 Capital CNY 92.80 million Shareholders Wang Jianhua, others Products Interior and exterior products No. employees 2,203 (as of May 31, 2022) Contacts Toyoda Gosei Co., Ltd.Public Relations Chihiro Suzuki inquiry@mlist.toyoda-gosei.co.jp
-
Senet Announces Network-Based Location Estimator
New Offering Location Enables Any LoRaWAN® End Device, Allowing Solution Providers to Incorporate Estimated Location Data into Applications at Low Cost PORTSMOUTH, N.H.--(BUSINESS WIRE)--Senet, Inc., a leading provider of cloud-based software and services platforms that enable global connectivity and on-demand network build-outs for the Internet of Things (IoT), today announced a new network-based Location Estimator. Senet’s Location Estimator uses the company’s public carrier-grade LoRaWAN® network and networks deployed by the company’s Extended Coverage partners to provide customers with location logic for asset tracking, location-enabled mapping, and any application that can benefit from estimated presence and proximity detection. Unique to Senet’s Location Estimator is that the end device connecting to the network does not need to be designed with specific geolocation technology, making any LoRaWAN device, regardless of its original intended purpose, location aware. Location Estimator is available immediately as an add-on to a Senet connectivity plan. While many location services require dedicated device hardware and frequent communication with the network which can increase costs and drain batteries quickly, Senet’s Location Estimator leverages the company’s existing and rapidly expanding public LoRaWAN network, including integration with over 870,000 Helium Network LoRaWAN hotspots, to deliver location information. Senet’s Location Estimator derives the location of any LoRaWAN device from the location of the gateway or gateways that relay any uplink message. Location accuracy is dependent on the number of gateways receiving the uplink messages from the device over time. This feature is optimized for applications which do not require precise geolocation and is targeted for use where estimated location data combined with application-specific environmental data meets the use-case requirements. “Many location services are over architected for the use cases they are being applied to, which unnecessarily increases the cost of devices, reduces battery life, and generates complexity of application development and service delivery. Knowing an estimated location and environmental data such as temperature, humidity, shock, and vibration are key for general asset tracking, supply chain, perishable food delivery, and many other applications,” said Bruce Chatterley, CEO of Senet. “With the expansion and densification of Senet’s network through participation in our LPWAN Virtual Network and integrations with partners like Helium, our Location Estimator provides a cost-effective alternative for a variety of fixed, mobile, and nomadic use cases where precision location isn’t needed.” With Total Cost of Ownership (TCO) being largely dependent on the cost and battery life of end devices, Senet’s Location Estimator makes it economically feasible for solution providers to explore new use cases where the combination of location and other sensor data can enhance the value proposition of their products and services. Example Mobile Location Use Cases Monitoring and reporting location and other data, like temperature, humidity, and shock are critical elements of the supply and distribution process. With Senet LoRaWAN networks available in major shipping ports and along key logistics corridors, application providers serving the logistics market now have access to location and other sensor data at a fraction of the cost of expensive and power-hungry cellular services. Example Nomadic Use Cases Understanding the stationary and in-transit location and state of assets like shipping containers, construction vehicles, pallets, and material can help improve logistics planning and project success. Knowing where your equipment and assets are improves utilization, supports maintenance planning, and boosts operational efficiency. Example Fixed Location Use Cases Ensuring the correct location of fixed assets and various elements of critical infrastructure is directly related to operational efficiency and safety. Guaranteeing that only authorized installation, maintenance, and moves are taking place can help prevent capital equipment loss, service disruption, and catastrophic events. For more information, schedule a meeting to visit Senet at LoRaWAN World Expo, July 6-7, 2022 in Paris or contact us at info@senetco.com or +1 877-807-5755. LoRaWAN® is a mark used under license from the LoRa Alliance®. About Senet, Inc. Senet develops cloud-based software and services used by Network Operators, Application Developers, and System Integrators for the on-demand deployment of Internet of Things (IoT) networks. In addition to industrial and commercial applications, Senet has designed smart meter networks for many municipal water utility districts across the United States, representing millions of households. With a multi-year head start over competing Low Power Wide Area Network technologies, Senet offers services in over one hundred and eighty countries and owns and operates one of the largest publicly available LoRaWAN® networks in the United States. Our disruptive go-to-market models and critical technical advantages have helped us become a leading connectivity provider with recognized expertise in building and operating global IoT networks. For additional information, visit www.senetco.com. Contacts Senet: James Gerber Crackle Communications 508-233-3391 senet@cracklepr.com
-
Westchester Capital Management UK Regulatory Announcement: Form 8.3 - Avast plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Westchester Capital Management, LLC/ Westchester Capital Partners, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Avast plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure July 5, 2022 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” Yes - NortonLifeLock Inc. 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 10p ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 12,297,436 1.18 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 12,297,436 1.18 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 10p ordinary CFD Decreasing long 250,000 513.68 GBp (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” none (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” none (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? no Date of disclosure: July 5, 2022 Contact name: Michael Bauco Telephone number: 914 741 5600 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. Contacts Westchester Capital Management
-
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
INGELHEIM, Germany & HAMBURG, Germany & MARCY-L’ÉTOILE, France--(BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients. “The rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR – is indeed a looming global crisis,” said Michel Pairet, Head of Boehringer Ingelheim’s Innovation Unit and Member of the Board of Managing Directors. “Antibiotic resistance kills about 1.27 million people globally every year1 and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR2, making it potentially deadlier than cancer.” Werner Lanthaler, CEO of Evotec added: “The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec’s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR.” “bioMérieux has a strong expertise in antimicrobial resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship),” said Alexandre Mérieux, bioMérieux Chairman and CEO. “Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with bioMérieux’ full commitment to sustain antibiotic efficacy for future generations.” Aurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models. Funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each, the 40 million EUR joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux’s market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim’s broad drug discovery and significant clinical development capabilities. Three partners committed to combat AMR Boehringer Ingelheim’s participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a 50 million EUR investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to 12 million EUR in AMR infection companies. bioMérieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance. Moreover, 80 percent of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation. Evotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company’s own pre-competitive pandemic preparedness and rapid response technology platform (“PRROTECT”), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU’s Innovative Medicines Initiative (“IMI”). References 1 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext#seccestitle102 https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf Please click on the following link for ‘Notes to Editors’ and ‘References’: https://www.boehringer-ingelheim.com/media-overview/press-releases/joint-venture-fight-antimicrobial-resistance Contacts Boehringer IngelheimCorporate AffairsHarro Ten Wolde55216 Ingelheim Phone: +49 151 61901069 Email: press@boehringer-ingelheim.com
-
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (the “TASE”). Based upon a review of the recent trading volume of BiomX’s common stock on the TASE and the costs associated with maintaining a presence on more than one stock exchange, BiomX’s management and its Board of Directors have concluded that it would be in the best interests of shareholders to have BiomX’s common stock listed on a single stock exchange. Under applicable Israeli law, the delisting of BiomX’s shares of common stock from trading on the TASE is expected to become effective in three months, on October 6, 2022. During this time, BiomX’s shares will continue to be traded on the TASE. Following the delisting of BiomX’s shares of common stock on the TASE, BiomX’s shares will continue to be listed on the NYSE American and all BiomX shares now traded on the TASE are expected to be transferred to the NYSE American where they can continue to be traded. About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Additional information is available at www.biomx.com, the content of which does not form a part of this press release. Safe Harbor This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses its expectations regarding the timing and benefits of delisting from TASE and expectation of continued listing on the NYSE American, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and, except as provided by law, BiomX expressly disclaims any obligation or undertaking to update forward-looking statements. Source: BiomX Inc. Contacts Investor Relations: LifeSci Advisors, LLC John Mullaly (617)-698-9253 jmullaly@lifesciadvisors.com BiomX, Inc. Anat Primovich Corporate Project Manager +972 (50) 697-7228 anatp@biomx.com
-
DIGITIMES: Why are Smart Cities the Future Momentum
TAIPEI, July 6, 2022 /PRNewswire/ -- DIGITIMES Research report shows that Taiwan's ICT industry development has shifted from focusing on hardware to hardware/software integration models. The industry is combining big data analysis and AI applications in public IoT to facilitate the development of smart city management. Tools such as IoT, AI, cloud computing, and communications technologies are efficiently integrated with urban infrastructure to ultimately produce economic benefits and improve quality of life. It is estimated that the business opportunities of smart cities will reach $2.6 trillion in 2025, mainly in the Asia Pacific region. This includes sectors such as smart poles, building, parking, monitor, government, transportation, fire protection, water conservancy and WITMED. Smart cities, with a massive business potential, will become the future momentum! DIGITIMES will have Dr. Ayesha Khanna, Co-Founder and CEO of Addo, to share her observation of new smart city applications as well as how technologies can improve people's life and government efficiency on July 21 smart city webinar. In the pre-event interview that asked about Taiwan's role in the smart city market, Dr. Khanna pointed out that Taiwan's expertise in semiconductor and hardware is important to smart cities' development as more data is being used to improve AI systems, resulting in rising demand for stronger infrastructure and hardware with next-generation AI semiconductors. Dr. Khanna believes that whether it is AI, robots, 3D printing, Internet of things or 5G, smart city's development should not start purely with technologies but the idea of assisting people to solve their problems or become the aspirational goal for citizens. When people want to have better energy and waste management in their city, designers can create an AI solution for monitoring energy usage that can turn streetlights on and off with a built-in smart lighting system. They can also build a centralized trash collection mechanism with sensors and have robots powered by AI to collect waste all around the neighborhoods to reduce traffic and road congestions. It is also important to collect and integrate publicly available data and data from the ecosystem's private firms to form a system. By combining data of taxi companies and traffic light operation, it reduces people's waiting time for taxies, while traffic congestion can also be significantly lowered with the system's assistance in rerouting or changing the traffic lights. Nowadays, because of the pandemic, the number of hospital visits via online meeting software or telemedicine services increased dramatically as people find it more convenient and efficient. The technologies used by medical care system are also making improvements with some designers beginning to adopt biometric sensors onto the terminals for the machines to collect more patients' data, giving doctors more information to make intelligent diagnosis, such as handheld ultrasound products that can be connected via smartphones for patients to check on themselves via AI or by medical staff nearby and then send results to their doctors. Technologies for remote medical care are a key area that many IT companies have devoted their R&D effort to. Ambulances built with remote medical care system can connect doctors with ambulances care assistants for them to do checkups while transporting patents to the hospital. The doctors can also make an examination over patients' injuries via a head-mounted display (HMD) to save time. However, all these innovations still rely on 5G to form connections. The technology allows devices to communicate with each other with its fast transmission speed and has brought a revolution to the manufacturing industry and factories. In Singapore, a lot of investments are being made for deploying 5G infrastructure throughout the city. This is also the case for many countries including the US. As smart systems are adopting more sensors to enhance their data collection ability, 5G's commercialization has become the key to unlock the potential of IoT. With telecom carriers worldwide keenly expanding their 5G infrastructure, Dr. Khanna is optimistic about the birth of more new smart systems and the rapid development of smart cities worldwide soon. In the end, the future of smart city will not be operated by one large central AI, but multiple small ones. Issues within smart cities' key sectors such as healthcare, energy and education will continue to be handled by government departments or public sector companies with them using AIs to optimize and create innovations for their services, Dr. Khanna said. Join DIGITIMES Asia smart city webinar in discovering the digital transformation of smart cities, find out how to build a smart city, and what are the applications and connected solutions that drive city extensive improvements, creating better quality of life for residents and business opportunities for enterprises. For more webinar information, please visit https://reurl.cc/j1KRgZ
-
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
– Mosunetuzumab could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin’s lymphoma – – Application is based on results from the pivotal Phase I/II study showing mosunetuzumab induced high and durable complete response rates in people with follicular lymphoma who received two or more prior therapies – – Mosunetuzumab is a fixed-duration treatment option with the potential to be administered in an outpatient setting – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. FL is the most common indolent (slow growing) form of non-Hodgkin’s lymphoma (NHL), a type of blood cancer, which often returns after initial therapy. The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022. “New therapeutic options are needed for follicular lymphoma, which often relapses after initial therapy and becomes increasingly difficult to treat each time it returns. Clinical trial results have demonstrated durable responses with mosunetuzumab in advanced follicular lymphoma, representing a step toward shifting the treatment paradigm,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Since mosunetuzumab does not require the collection or genetic modification of patient cells, it could become an effective, fixed-duration outpatient option without the barriers of travelling to a major academic center.” The BLA is based on positive results from the pivotal Phase I/II GO29781 study of mosunetuzumab, which showed high complete response (CR) rates, with the majority of responders (57% [95% CI: 49-70]) maintaining responses for at least 18 months, and manageable tolerability in people with heavily pretreated FL. After a median follow-up of 18.3 months, the CR rate was 60% (n=54/90) and the objective response rate was 80% (n=72/90). The median duration of response among those who responded was 22.8 months (95% CI: 9.7-not estimable). The most common adverse event (AE) was cytokine release syndrome (39%; n=86/218), which was generally low grade (grade 1: 25.6%; grade 2: 14%; grade 3: 2.3%; grade 4: 0.5%), and all events resolved. Other common AEs (>20%) included fatigue, headache, neutropenia, fever and hypophosphatemia. Treatment was administered without mandatory hospitalization. Results were presented for the first time in December 2021 at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Priority Review designation is granted to medicines that the FDA considers to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. The FDA granted Breakthrough Therapy Designation (BTD) to mosunetuzumab for the treatment of adults with R/R FL who have received at least two prior systemic therapies in June 2020 and Orphan Drug Designation in December 2018. BTD is designed to accelerate the development and review of medicines intended to treat serious or life-threatening conditions with preliminary evidence that indicates they may demonstrate substantial improvement over existing therapies. The European Commission granted conditional marketing authorization for mosunetuzumab for the treatment of people with R/R FL who have received at least two prior systemic therapies in June 2022. A robust development program for mosunetuzumab is ongoing including two Phase III studies: CELESTIMO investigating mosunetuzumab plus lenalidomide in second-line plus (2L+) FL, and SUNMO, investigating mosunetuzumab plus Polivy® (polatuzumab vedotin) in 2L+ diffuse large B-cell lymphoma (DLBCL). About the GO29781 Study The GO29781 study [NCT02500407] is a Phase I/II, multicenter, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of mosunetuzumab in people with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Outcome measures include complete response rate (best response) by independent review facility (primary endpoint), objective response rate, duration of response, progression-free survival, safety and tolerability (secondary endpoints). About Follicular Lymphoma Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin’s lymphoma, accounting for about one in five cases. It typically responds well to treatment but is often characterized by periods of remission and relapse. The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis. In the United States, it is estimated that approximately 13,000 new cases of FL will be diagnosed in 2022. About Mosunetuzumab Mosunetuzumab is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for mosunetuzumab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma and other blood cancers. About Polivy® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies. The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patient’s doctor may stop or adjust a patient’s treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects. Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patient’s doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns Infusion-related reactions: A patient may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of the infusion Infections: Patients should contact their healthcare team if they experience a fever of 100.4°F or higher, chills, cough, or pain during urination. Also, a patient’s doctor may give medication before giving Polivy, which may prevent some infections, and monitor blood counts throughout treatment with Polivy. Treatment with Polivy can cause severe low blood cell counts Rare and serious brain infections: A patient’s doctor will monitor the patient closely for signs and symptoms of these types of infections. Patients should contact their doctor if they experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of the skin or the white part of the eyes. Patients may be at higher risk if they already have liver problems or are taking other medication Side effects seen most often The most common side effects during treatment were: Low blood cell counts (platelets, red blood cells, white blood cells) Nerve problems in arms and legs Tiredness or lack of energy Diarrhea Nausea Fever Decreased appetite Infections Polivy may not be for everyone. A patient should talk to their doctor if they are: Pregnant or may be pregnant: Data have shown that Polivy may harm an unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for at least 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for at least 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for at least 2 months after the last dose These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit http://www.Polivy.com for the full Prescribing Information for additional Important Safety Information. About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. Contacts Media Contact: Priscilla White (650) 467-6800 Advocacy Contact: Cem Mangir (202) 251-4037 Investor Contacts: Loren Kalm (650) 225-3217 Bruno Eschli 011 41 61 687 5284
-
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers, and a dose-escalation and parallel design, multiple-dose study in adult patients with moderate to severe atopic dermatitis. The study will be used to evaluate the safety, tolerability and efficacy of IMG-007 in patients with atopic dermatitis. Additional details will be found at clinicaltrials.gov, using identifier NCT05353972. "Dosing the first participant is an important milestone for the IMG-007 program," said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene. "We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide." Dr Jean-Louis Saillot, Chief Development Officer of Inmagene, said, "IMG-007 blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential. We welcome the start of the IMG-007 clinical program with the hope of developing an innovative, safe and effective treatment option for patients with atopic dermatitis and other immunological diseases." Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "This is an exciting step towards taking our novel drug candidates into immunological diseases, where Inmagene has significant expertise, as we work to maximize the impact of our drug discovery engine." About IMG-007 IMG-007 is a novel antagonistic monoclonal antibody targeting the OX40 receptor. It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage. Inmagene has an exclusive option to in-license IMG-007's global rights. About OX-40 and Atopic Dermatitis OX40 is a costimulatory receptor member of the tumor necrosis factor receptor (TNFR) superfamily expressed predominantly on activated T cells. The ligation of OX40 by its ligand OX40L leads to enhanced T cell survival, proliferation, and effector functions. Preclinical research results show that IMG-007 can bind to human OX40 receptor with high affinity, thereby inhibit the binding of OX40 to OX40L, reducing OX40L-dependent downstream signaling and cytokine release by OX40+ T cells. By selectively shutting down OX40+ T cell function, IMG-007 may provide a treatment option for pathological OX40+ T cell-mediated immune diseases, such as atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin condition that is estimated to affect 8-19% of children and 2-5% of adults in US, Europe, and East Asia.[1],[2],[3] About Inmagene Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building a robust pipeline of nearly twenty drug development programs. Inmagene's most advanced drug candidate is IMG-020 (izokibep), which has successfully met the endpoints in global phase II studies for both psoriasis and psoriatic arthritis ("PsA"). It has received the IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for phase III studies in plaque psoriasis. Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis. In addition, IMG-004 and IMG-007, both of which with global rights, are in global phase I studies. Believing in "Borderless Innovation", the Inmagene team strives to integrate efficient resources worldwide to develop novel therapeutics for global patients. Based on its proprietary QuadraTek™ drug discovery platform, Inmagene is operating 12 "Smart Innovation" programs to create and develop drug candidates with global rights. Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates. For more information, please visit: www.inmagenebio.com About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of over 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Inmagene's and/or HUTCHMED's current expectations regarding future events, including expectations regarding the therapeutic potential of IMG-007 for the treatment of patients with atopic dermatitis and other immunological diseases, the further clinical development of IMG-007, expectations as to whether clinical studies of IMG-007 would meet their primary or secondary endpoints, and expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of IMG-007 to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of IMG-007 for a targeted indication; the sufficiency of funding; and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of various risks applicable to HUTCHMED, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. Neither Inmagene nor HUTCHMED undertakes to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. [1] Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. doi:10.1016/j.anai.2020.12.020 [2] Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi:10.1111/all.13401 [3] Ständer S. Atopic Dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911
-
K-SWISS Athlete, Cameron Norrie, Beats David Goffin to Advance to the Semi-Finals at Wimbledon
LOS ANGELES, July 6, 2022 /PRNewswire/ -- Iconic American heritage Tennis brand, K-SWISS, is thrilled to announce their sponsored athlete, Cameron Norrie, will advance to the Semi Final round at Wimbledon after beating David Goffin in an exciting 5 set match. The #1 ranked British player, who is currently ranked #12 ATP seeks to continue his best run ever at a Grand Slam title. Norrie has been a K-SWISS athlete since 2020. "Our partnership with Cam began three years ago. We liked this playing style and approach to owning everything he does on court. Last year we could see his improvement and confidence grow with every match, starting 2021 ranked in the seventies and finishing the year at number ten. As we continue to invest in our tennis business globally, re-signing Cam to be our global ambassador was a top priority, we were very excited and proud for Cam to be part of our K-Swiss Team through 2024," says Dave Grange, International Brand President of K-Swiss. During the match, Norrie's footwear of choice continues to be the K-SWISS Ultrashot 3. The new shoe is built for the competitive, aggressive, and powerful tennis player who demands the highest level of performance. The Ultrashot 3 offers maximum energy return with Surge 7.0 midsole technology, 360 Plantar Chassis Support for unlimited lateral movement, and Dragguard 7.0 incorporated into a new durable outsole with superior grip and traction. In addition to the footwear, Norrie is also wearing the newly redesigned K-SWISS apparel, the Heritage S/S shirt and the Supercharge shorts, which are innovatively designed for fit and function. The lightweight materials incorporated with stealth angles and asymmetrical side create an aerodynamic progressive look that redefines the classic tennis outfit. Today, Norrie looked and played like a champion. The K-SWISS styles similar to what Norrie wore today at Wimbledon are available on K-Swiss.com. ABOUT K-SWISS From the beginning, K-Swiss has been driven by an entrepreneurial spirit when two Swiss brothers moved to California to create a footwear brand focused on tennis. As avid skiers, the brothers took inspiration from leather ski boots to create tennis shoes that supported the aggressive side-to-side movement. Introduced In 1966, the K-Swiss Classic was the world's first all-leather tennis shoe. It quickly gained worldwide acclaim and became a style statement both on and off the court, worn casually in country clubs and just as fashionably on city streets. Now, 57 years later, K-Swiss is building from its heritage as an American tennis brand and writing new chapters in its storied history. Paying homage to the hard work of our founders and the competitive nature of the game that inspired it all, K-Swiss is dedicated to outfitting and inspiring the next generation of tennis players. Media Contacts:K-SWISSOlivia@kruppgroup.com Cameron Norrie (Photo by Justin Setterfield/Getty Images)
-
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Missfresh Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Missfresh Limited (“Missfresh” or “the Company”) (NASDAQ: MF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Missfresh announced on July 1, 2022, that an internal review revealed that certain revenues in fiscal 2021 “may have been inaccurately recorded.” According to the Company, the review uncovered “questionable transactions” recorded by the Next-Day Delivery Business Unit, including “undisclosed relationships between suppliers and customers, different customers or suppliers sharing the same contact information, and/or lack of supporting logistics information.” If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Edgio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgio, Inc. (“Edgio” or “the Company”) (NASDAQ: EGIO) f/k/a Limelight Networks, Inc. (NASDAQ:LLNW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
Deep Longevity Announces Important Operational Update
HONG KONG, July 6, 2022 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a Hong Kong-based AI innovator and a leading provider of deep biomarkers of aging and longevity is pleased to announce several important updates which contribute to its growing journey. Hiring of New Chief Executive Officer Deep Longevity has hired a new Chief Executive Officer, Deepankar (Deep) Nayak, to bring experienced professional talent to redefine the strategy of the company, and take the organisation forward. Deep has over 17 years of experience in technology consulting having worked with large pharmaceutical customers in the United States ("US"), United Kingdom ("UK"), Europe, Japan and the Middle East. Building and Commercialisation of Aging Clocks Deep Longevity is committed to building and commercialising various aging clocks using artificial intelligence ("AI") led deep learning models. The company is applying special focus to the MindAge© offering as it seek to tap into the robust demand seen in the virtual mental health care market. The total addressable market is approximately US$89 billion (or approximately HK$694.2 billion) in the US only. MindAge© Deep Longevity is considering the creation of an enterprise grade MindAge© offering (web and app based) directed at large and mid-sized employers in the US, UK and Europe, which will be the platform of choice for employees to manage their virtual mental well-being in a safe, secure, private and personalized environment within the workplace. This will be the company's main focus for 2022 and 2023. Collaboration with Dr. Nancy Etcoff Deep Longevity announced its collaboration with Dr. Nancy Etcoff of Harvard Medical School on 21 June 2022 to create a virtual mental health offering through the deep learning based biomarkers of aging and longevity. In co-authorship with Dr. Etcoff, Deep Longevity has published an article in Aging-US describing a machine learning approach to human psychology: "Optimizing future well-being with artificial intelligence: Self-organizing maps (SOMs) for the identification of islands of emotional stability." Development of FuturSelf FuturSelf, a free self-help application has been developed in collaboration with a leading European insurtech innovation hub to demonstrate the potential of the system. Data obtained on FuturSelf will be used to further develop Deep Longevity's digital approach via a minimal viable product (MVP) on mental health with the aim of offering the application via a business-to-business (B2B) software as a service (SaaS)© model to insurance companies, large corporates and other employers to allow their employees to track and nurture their own mental health and wellbeing. To address how mental health can be managed to help employees better cope with job demands and maximize their productivity, Deep Longevity is focused on providing highly scalable and commercial solutions that can be applied cost effectively across all industries. Using Deep Longevity's digital approach to managing mental health, an invaluable feedback loop is created that can help employees thrive by increasing their motivation and productivity or allowing them to seek important and timely emotional support when required. On a per-employee basis, the cost to employers to provide this essential human resource function can be minimal. Ongoing discussions with large insurance companies and other multinational corporations suggest that the commercial opportunity for Deep Longevity (through FuturSelf and other applications) is immense and geographically scalable across all markets world-wide. Jamie Gibson, Chief Executive Officer of the Company said, "As one of the forerunners in the longevity AI market, we are thrilled to achieve this remarkable milestone together with the world's top-notch scientists. We are confident about the future of integrating deep learning AI technologies in human psychology and the development of digital solution to improve people's mental health and overall well-being." Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity commented, "I've dedicated a large part of my life towards furthering the science of Longevity and am delighted to announce that DL has found a person who not only shares that passion but also brings the experience of building and commercializing products that will help us take our innovation to global markets. DL's aging clocks will underpin the research and development that the Longevity industry is going to witness and I'm confident Deep will take our aging clocks to different industries as we discover new applications of this technology." -Ends- About Deep Longevity Deep Longevity is a wholly owned subsidiary of Endurance Longevity (SEHK:0575.HK), a publicly-traded company. Deep Longevity develops explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions about interventions that may slow down or reverse the aging processes. Deep Longevity developed the Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence: ETP Ventures; the Human Longevity and Performance Impact Venture Fund; BOLD Capital Partners; Longevity Vision Fund; LongeVC; Michael Antonov, the co-founder of Oculus; and other expert AI and biotechnology investors. Deep Longevity established a research partnership with Human Longevity, Inc., one of the most prominent longevity organizations to provide a range of aging clocks to a network of advanced physicians and researchers. https://www.deeplongevity.com/ About Endurance Longevity (Stock code: 0575.HK) Endurance Longevity is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. www.endurancerp.com This press release is distributed by LBS Communications Consulting Limited.
-
How Javer Became One of the Best Companies to Work in Mexico
MONTREAL--(BUSINESS WIRE)--Reaching a genuine sustainability strategy that engages all stakeholders with the utmost care and respect is crucial for companies seeking to build solid long-term results. Today, employees, consumers, and investors are constantly looking for companies that embrace a holistic business approach. Javer has become a benchmark of sustainability in Mexico, especially in human resources management, which has allowed it to be recognized as one of the best companies to work for in Mexico. Great Place To Work (GPTW) is an international certification awarded to companies that create an exceptional workplace environment. GPTW uses the Trust Index, a KPI (key performance indicator) for measuring the commitment of the people who are part of the company; the higher it is, the greater the trust. This certification has 5 dimensions: credibility, respect, fairness, pride, and camaraderie. GPTW survey has allowed Javer to measure, track, and strengthen different aspects that contribute to the quality of working life. The company has historically stood out in two categories: pride and camaraderie, thanks to its friendly working environment, as multiple activities are carried out to forge strong bonds and establish good communication among leaders and employees, which is reflected in its employees expressing a sense of pride being part of this company. Javer's high ranking on the list is the result of the implementation of several programs, including: Approach on talent retention: The company provides different benefits and perks to employees to encourage their professional growth. Equality and diversity: Javer is attached to the principles of inclusion, empathy, and, tolerance, highlighting the fact that its team has a significant number of women holding leadership positions, as well as the pursuit of equal opportunities for all. Occupational health and safety: Javer is committed to ensuring an excellent quality of life for its employees. This encompasses topics such as mental health, nutrition, information sessions on COVID-19. Over the past years, Javer has steadily improved in the GPTW's national ranking within the 500 to 5,000 employee Top 100 Companies category. In 2022, it ranked 35th, with much further progress. There is no doubt that Javer's success in the management of its human resources will allow it to continue consolidating its position as one of the best Mexican companies in the construction industry. Read the full release at: Emerging Exchange Contacts Marijose Vasquez info@emergingexchange.com+1 646 419 4004
-
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
harrison.ai and Sonic Healthcare join forces to launch 'franklin.ai', bringing Artificial Intelligence (AI) to pathology
franklin.ai aims to apply the latest methodologies in artificial intelligence (AI) to put groundbreaking AI tools into the hands of pathologists. SYDNEY, July 6, 2022 /PRNewswire/ -- harrison.ai, the clinically led healthcare AI platform and Sonic Healthcare (ASX:SHL), the global medical diagnostics leader, have this week officially launched 'franklin.ai', a joint venture to advance patient care by integrating digital pathology tools into daily clinical practice. The global partners have appointed Stephen Ruffels as Chief Executive Officer of franklin.ai, bringing 20 years of technology leadership and medical device experience to the newly formed venture. Stephen, formerly harrison.ai's Chief Operating Officer, will oversee a team of more than 70 specialist engineers, data scientists and clinical experts by the end of 2023 to rapidly develop and commercialise new artificial intelligence (AI) methodologies for pathology. franklin.ai will provide pathologists with a digital assistant, using state-of-the-art AI technology in the form of tools that enhance diagnostic accuracy and efficiency. The venture combines harrison.ai's depth of expertise and comprehensive AI methodologies with Sonic Healthcare's global clinical experience and expertise to unlock the potential of digital pathology. The new venture is supported by key hires, including General Manager Peter Dassos (formerly Director of Product at ResMed), and Head of Talent Celeste Kocabay (formerly Atlassian and Investible). Stephen Ruffels, CEO of franklin.ai, said: "The global healthcare system has changed, and today we face many new challenges that require groundbreaking technological and digital advancements. We have spent months building the right team to work hand-in-hand with pathologists to develop AI-powered tools that will augment their pivotal role at the heart of the healthcare system. We are excited to see the partnership between harrison.ai and Sonic Healthcare grow stronger by the day." Dr Aengus Tran, Co-Founder and CEO of harrison.ai, said: "The launch of franklin.ai marks a milestone in our partnership with Sonic Healthcare. Combining the harrison.ai process and technology platform with Sonic Healthcare's expertise is what we believe to be the fastest way to achieve our common goal of improving the capacity and quality of pathology services globally." "We are also thrilled to announce that our former COO, Stephen Ruffels, has been appointed as CEO of franklin.ai. Stephen was one of the first to join us and has contributed enormously to the success of harrison.ai in the last two years. I am confident that Stephen will uphold the values of both harrison.ai and Sonic Healthcare with his leadership and expertise in medical devices and will drive our mission in the pathology sector." Dr Colin Goldschmidt, CEO of Sonic Healthcare, adds, "I am delighted with our new partnership, one which will strengthen our digital pathology endeavours on a global scale. Laboratory medicine informs almost every aspect of modern medicine, especially the diagnosis of cancer. With franklin.ai, we are taking a big step forward in the field of digital pathology, and we look forward to playing a leadership role in this important new area of modern medicine." - END - About franklin.ai franklin.ai is a joint venture between global medical diagnostic leader Sonic Healthcare and healthcare AI platform harrison.ai with a mission to put groundbreaking artificial intelligence (AI) in the hands of pathologists globally and benefit millions of patients. About harrison.ai harrison.ai is a clinician-led technology platform combining human intelligence with artificial intelligence (AI), building a range of ventures to change the face of healthcare and benefit millions of patients every day. With a vision to redefine what's possible in healthcare through AI technology, harrison.ai works with ventures to develop, commercialise and deploy AI tools that support clinical diagnosis. These include working with Virtus Health Limited to develop AI in IVF and the world's most comprehensive AI clinical decision-support solutions for diagnostic imaging in its venture with I-MED Radiology Network annalise.ai. Most recently, partnering with Sonic Healthcare to put AI tools in the hands of pathologists with franklin.ai. Each venture is based on the harrison.ai platform and fuses harrison.ai's partner company's deep clinical expertise and frameworks with the harrison.ai technology. About Sonic Healthcare Sonic Healthcare is one of the world's leading providers of medical diagnostics, with a reputation for excellence in laboratory medicine/pathology, radiology and primary care medical services, across operations in Australasia, Europe and North America.
